Chicago Sky Blue has previously been shown to inhibit the DNA recombinase Rad51 (48) and glutamate uptake into synaptic vesicles (49), and is clearly not suitable for the treatment of either prion or Alzheimer disease or a promising starting point for a medicinal chemistry program. Here, RAD51 is linked to early-onset autosomal dominant Alzheimer disease.